| Prev Close | 81.36 |
| Day Low/High | 81.25 / 83.63 |
| 52 Wk Low/High | 68.25 / 131.94 |
BioMarin Pharmaceutical Inc. (BMRN)
82.97
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 181.53B |
| Market Cap | 14.77B |
| P/E Ratio | 18.29 |
| Div & Yield | N.A. (N.A) |
Get Used to the New Market Reality
Algos think faster and react faster than humans can.
A Blueprint for Highflier Stability
Cautionary tales that the IPO window might be closing at last.
Wait for the All-Clear
In other words, wait for the downgrades.
Stocks Love Fed's Bond Addiction
Stocks are moving higher as the Fed said it will keep buying bonds. Rite Aid is up and Pier One is down, Take Two is a steal.
Biotech's Next Big Thing: BioMarin
BioMarin's R&D update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet.
Mad Money Uncovered: ASCO
Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken
Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
A Deep Post-Decline Analysis Part 2
Stocks that defy correction and those ripe for correction.
The Beat Goes On
The slow, steady push higher continues.
The Next Big Thing In Biotech: BIO CEO Conference
Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.
Trick of the Trading
It's the bulls' turn to shine.
The Next Big Thing in Biotech: J.P. Morgan Conference
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo
Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.
Waiting for the Pattern to Break
Trading on the S&P 500 has remained tightly contained so far.
Biotech Is Booming
Despite the solid performance so far this year, there's still time to get on board and ride the profit train.
